Research programme: opioid prodrugs - NeurogesXAlternative Names: NGX-6052
Latest Information Update: 04 Jun 2009
At a glance
- Originator NeurogesX
- Mechanism of Action Opioid receptor agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Pain
Most Recent Events
- 27 Aug 2007 Preclinical trials in Pain in USA (unspecified route)